Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06471829 · ClinicalTrials.gov registry record · Phase 2

A Trial of Lu AG13909 in Adult Participants With Cushing's Disease

A Phase 2 study of Cushing's Disease, sponsored by H. Lundbeck A/S.

Recruiting
Registry status
Phase 2
Development phase
18
Enrollment target
20
Study locations

NCT06471829 is a Phase 2 study of Cushing's Disease that is actively recruiting participants, run by H. Lundbeck A/S. The registered enrollment target is 18 participants, below the 128-participant average among 5 other Cushing's Disease trials with a reported enrollment target (86% lower). The trial reports 20 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06471829, a Phase 2 study of Cushing's Disease, is actively recruiting participants, sponsored by H. Lundbeck A/S.

RECRUITING
Registry status
Phase 2
Development phase
18 participants
Enrollment target
20
Study locations

Study Summary

This trial will evaluate the effects of Lu AG13909 in adult participants with Cushing's disease (CD). CD is a rare and serious disorder where the body makes too much of a hormone called cortisol. The main goals of this trial are to learn about 1. the effect of Lu AG13909 on cortisol levels. 2. the safety and tolerability of Lu AG13909. 3. the pharmacokinetic parameters of Lu AG13909 (how the drug is absorbed, distributed, and processed by the body).

Conditions Studied

Cushing's Disease

Interventions

  • DRUG Lu AG13909

Study Locations (20)

Other

  • Hopital Louis Pradel - Bron
  • APHP - Hôpital Bicêtre - Le Kremlin-Bicêtre
  • Centre Hospitalier Universitaire De Lille - Lille
  • Hopital Haut-Leveque - Pessac
  • Ltd Aversi Clinic - Tbilisi
  • Semmelweis Egyetem, Belgyogyaszati es Onkologiai Klinika - Budapest
  • Debreceni Egyetem Klinikai Kozpont - Debrecen
  • University Hospital of Pecs - Pécs
  • AOU Policlinico G. Martino - Messina
  • Azienda Ospedaliera Universitaria Sant'Andrea - Rome
  • AOU Citta della Salute e della Scienza di Torino - Torino
  • Institutul National de Endocrinologie "C.I. Parhon" - Bucharest

Europe

  • Assistance Publique Hopitaux de Marseille (AP-HM) - Hopital La Conception - Marseille
  • Ltd Tbilisi Central Hospital - Tbilisi
  • National Institute of Endocrinology - Tbilisi
  • Multiprofile Clinic Consilium Medulla Ltd - Tbilisi
  • Azienda Ospedale Università di Padova - Padua
  • Azienda Ospedaliero-Universitaria Pisana - Pisa

Michigan

  • University of Michigan - Ann Arbor

Cedex 09

  • Centre Hospitalier Universitaire d'Angers - Angers

Trial Details

FieldValue
Enrollment Target 18 participants
Start Date 2024-06-19
Est. Completion 2027-11-30
Phase Phase 2

Sponsor

H. Lundbeck A/S

72 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06471829

The ClinicalTrials.gov registry entry for NCT06471829 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 128-participant average among 5 other Cushing's Disease trials with a reported enrollment target (86% lower). The listed sponsor is H. Lundbeck A/S, which has 72 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cushing's Disease appearing as the primary indexed condition, and to 1 intervention - of which Lu AG13909 is the first listed.

NCT06471829 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Other, Europe, Michigan.

Frequently Asked Questions

What is clinical trial NCT06471829 about?

NCT06471829 is a clinical study titled "A Trial of Lu AG13909 in Adult Participants With Cushing's Disease". This trial will evaluate the effects of Lu AG13909 in adult participants with Cushing's disease (CD). CD is a rare and serious disorder where the body makes too much of a hormone called cortisol. The main goals of this trial are to learn about 1. the effect of Lu AG13909 on cortisol levels. 2. the ...

What is the current status of trial NCT06471829?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2024-06-19. Estimated completion is 2027-11-30.

What conditions does trial NCT06471829 study?

This clinical trial studies the following conditions: Cushing's Disease.

What interventions are being tested in trial NCT06471829?

The interventions under investigation include: Lu AG13909 (DRUG).

Who is sponsoring clinical trial NCT06471829?

This trial is sponsored by H. Lundbeck A/S, which has 72 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06471829 being conducted?

This trial has 20 study locations across Michigan, Cedex 09, Europe. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Cushing's Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Cushing's Disease

All registered trials for this condition

Michigan

All trials with a study site in Michigan

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.